South Korea
· Delayed Price · Currency is KRW AptaBio Therapeutics Statistics
Total Valuation
AptaBio Therapeutics has a market cap or net worth of KRW 206.74 billion. The enterprise value is 174.14 billion.
| Market Cap | 206.74B |
| Enterprise Value | 174.14B |
Important Dates
The next estimated earnings date is Thursday, November 14, 2024.
| Earnings Date | Nov 14, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
AptaBio Therapeutics has 24.73 million shares outstanding. The number of shares has increased by 0.05% in one year.
| Shares Outstanding | 24.73M |
| Shares Change (YoY) | +0.05% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 31.96% |
| Owned by Institutions (%) | 1.30% |
| Float | 16.76M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 90.71 |
| PB Ratio | 3.72 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -11.41 |
| EV / Sales | 84.73 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -10.24 |
Financial Position
The company has a current ratio of 26.59, with a Debt / Equity ratio of 0.31.
| Current Ratio | 26.59 |
| Quick Ratio | 23.24 |
| Debt / Equity | 0.31 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.93 |
| Interest Coverage | -5.79 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Capital (ROIC) | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -7.34% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -7.34% |
| 50-Day Moving Average | 9,091.80 |
| 200-Day Moving Average | 7,899.20 |
| Relative Strength Index (RSI) | 50.61 |
| Average Volume (20 Days) | 213,943 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, AptaBio Therapeutics had revenue of KRW 2.06 billion and -15.27 billion in losses. Loss per share was -684.66.
| Revenue | 2.06B |
| Gross Profit | 156.29M |
| Operating Income | -17.66B |
| Pretax Income | -19.07B |
| Net Income | -15.27B |
| EBITDA | -17.12B |
| EBIT | -17.66B |
| Loss Per Share | -684.66 |
Balance Sheet
The company has 48.90 billion in cash and 15.78 billion in debt, giving a net cash position of 33.12 billion or 1,339.28 per share.
| Cash & Cash Equivalents | 48.90B |
| Total Debt | 15.78B |
| Net Cash | 33.12B |
| Net Cash Per Share | 1,339.28 |
| Equity (Book Value) | 50.57B |
| Book Value Per Share | 2,244.37 |
| Working Capital | 55.35B |
Cash Flow
In the last 12 months, operating cash flow was -15.76 billion and capital expenditures -1.24 billion, giving a free cash flow of -17.00 billion.
| Operating Cash Flow | -15.76B |
| Capital Expenditures | -1.24B |
| Free Cash Flow | -17.00B |
| FCF Per Share | -687.53 |
Margins
| Gross Margin | 7.60% |
| Operating Margin | -859.43% |
| Pretax Margin | -927.94% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | -827.33% |
Dividends & Yields
AptaBio Therapeutics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.05% |
| Shareholder Yield | -0.05% |
| Earnings Yield | -8.19% |
| FCF Yield | -8.22% |
Stock Splits
The last stock split was on August 24, 2021. It was a forward split with a ratio of 2.
| Last Split Date | Aug 24, 2021 |
| Split Type | Forward |
| Split Ratio | 2 |
Scores
AptaBio Therapeutics has an Altman Z-Score of 1.44. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.44 |
| Piotroski F-Score | n/a |